Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
Publications
Publications
  • October 2014 (Revised July 2016)
  • Supplement
  • HBS Case Collection

Gilead: Hepatitis C Access Strategy (B)

By: V. Kasturi Rangan
  • Format:Print
  • | Language:English
  • | Pages:7
ShareBar

Abstract

While the "Gilead: Hepatitis-C Access Strategy (A)" case (HBS No. 515-025) poses questions on what the company should do with respect to hard-hit countries like Egypt and India, the (B) case provides the answer. In both cases, the company chose to pursue a proactive strategy to enable access at affordable prices.

Keywords

Emerging Markets; Health Industry; Pharmaceutical Industry

Citation

Rangan, V. Kasturi. "Gilead: Hepatitis C Access Strategy (B)." Harvard Business School Supplement 515-044, October 2014. (Revised July 2016.)
  • Purchase

About The Author

V. Kasturi Rangan

Marketing
→More Publications

Related Work

    • October 2014 (Revised July 2016)
    • Faculty Research

    Gilead: Hepatitis C Access Strategy (B)

    By: V. Kasturi Rangan
    • April 2020 (Revised July 2022)
    • Faculty Research

    Gilead: Hepatitis C Access Strategy (A) and (B)

    By: V. Kasturi Rangan
Related Work
  • Gilead: Hepatitis C Access Strategy (B) By: V. Kasturi Rangan
  • Gilead: Hepatitis C Access Strategy (A) and (B) By: V. Kasturi Rangan
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College